MedNous interviews Professor Amit Nathwani

MedNous recently interviewed Professor Amit Nathwani, Chief Executive Officer of UCLTF portfolio company NovalGen. He shares his views for their article, ‘Bispecific antibody development gains momentum’.

Read the article here: 

MedNous: published in the March 2021 edition of MedNous, a publication of Evernow Publishing Ltd.

Related Content

We make UCL’s research physical and life sciences ideas happen.